NFE2L2: Nuclear factor erythroid 2-related factor 2
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles.
- Drugs that act on it: 1
- With a US drug page: 1
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Drug | US approval | Mechanism | Action | Warnings |
|---|---|---|---|---|
| Omaveloxolone | Approved | Nuclear factor erythroid 2-related factor 2 activator | Activator | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Immunodeficiency, developmental delay, and hypohomocysteinemia
- 0.77
- Squamous cell lung carcinoma
- 0.59
- Head and neck squamous cell carcinoma
- 0.51
- Abnormality of the skeletal system
- 0.46
- Lung carcinoma
- 0.40
- Esophageal squamous cell carcinoma
- 0.40
- Esophageal adenocarcinoma
- 0.38
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- NFE2L2
- Related
- Keap1/Nrf2
Drugs and mechanisms are from ChEMBL CHEMBL1075094 (CC BY-SA 3.0). Gene name, function (UniProt Q16236, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets